Description
Lenvatinib (often branded as Lenvima) is a targeted kinase inhibitor prescribed to treat various types of cancers, including thyroid, liver, kidney, and endometrial cancers. The 4mg dose is an oral hard capsule used for daily treatment or for adjusting dosages. [1, 2, 3, 4]
Appearance and Physical Description
- Form: Hard gelatin capsule.
Mechanism of Action
Common Indications
Lenvatinib is approved for:
- Differentiated Thyroid Cancer (DTC): Locally recurrent or metastatic, progressive disease that is radioactive iodine-refractory.
- Hepatocellular Carcinoma (HCC): First-line treatment for unresectable liver cancer.
- Renal Cell Carcinoma (RCC): Advanced kidney cancer, typically taken in combination with everolimus.

Reviews
There are no reviews yet.